POZ October-November 2018
POZ October-November 2018
In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Features
The Role of a Lifetime
Charles Sanchez’s HIV journey inspired his hit web series, “Merce.”
Calculated Risk
Understanding the connections between sex work and HIV
Picking Up the Pieces
The Impact of Hurricane Maria on HIV
Los Fundamentos del VIH/SIDA
Aprende más sobre la prevención y el tratamiento del VIH para mantenerse saludable.
Editor’s Letter
Ten Years Gone
Our current cover subject, Charles Sanchez, talks combining his acting skills and HIV activism to create a musical comedy web series.
POZ Q+A
Stronger Together
OutServe-SLDN assists military living with HIV who are facing more challenges to serving their country.
POZ Planet
Seaside Remembering
Provincetown’s AIDS memorial “stops one ocean moment in time.”
“Dangerous Complacency”
Why ACT UP protested two AIDS-themed art exhibits at the Whitney
A “Milestone” in HIV Criminalization
Global experts agree: Science does not back HIV crime laws.
10s Across the Board!
Pose and the Latex Ball serve HIV realness.
Voices
Wake-Up Call
Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), analyzes data from a 2018 UNAIDS report.
The Midterms
AIDS United reminds people living with HIV that the 2018 election isn’t just about seats in Congress.
Spotlight
#AIDS 2018
A social media recap of AIDS 2018.
Everyday
Everyday — October/November 2018
Here are some important dates in AIDS history.
Care and Treatment
Major Study Validates “U=U”
The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.
FDA Approves Janssen’s Symtuza
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
Zepatier Zaps Acute Hep C in 8 Weeks
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
PrEP Tied to HIV Decline
This association held true even when researchers controlled for changing rates of viral suppression of HIV in 2012 to 2016 records.
Research Notes
Prevention: HIV Vaccine
Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.
Treatment: Merck’s Doravirine
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
Cure: Gene-Editing Method
Scientists have discovered a swifter and more precise way to edit the genome of immune cells, opening doors for cancer and HIV therapies.
Concerns: Global Funding
After a decade of phenomenal growth, donor funding for low- and middle-income nations fell 7 percent between 2012 and 2017.
Heroes
Surviving Still
Jesús Guillén fights for HIV long-term survivors.
Digital Edition
POZ October/November 2018
Read the digital edition!
